Cargando…

Trigger-Responsive Gene Transporters for Anticancer Therapy

In the current era of gene delivery, trigger-responsive nanoparticles for the delivery of exogenous nucleic acids, such as plasmid DNA (pDNA), mRNA, siRNAs, and miRNAs, to cancer cells have attracted considerable interest. The cationic gene transporters commonly used are typically in the form of pol...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajendrakumar, Santhosh Kalash, Uthaman, Saji, Cho, Chong Su, Park, In-Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485767/
https://www.ncbi.nlm.nih.gov/pubmed/28587119
http://dx.doi.org/10.3390/nano7060120
_version_ 1783246137430376448
author Rajendrakumar, Santhosh Kalash
Uthaman, Saji
Cho, Chong Su
Park, In-Kyu
author_facet Rajendrakumar, Santhosh Kalash
Uthaman, Saji
Cho, Chong Su
Park, In-Kyu
author_sort Rajendrakumar, Santhosh Kalash
collection PubMed
description In the current era of gene delivery, trigger-responsive nanoparticles for the delivery of exogenous nucleic acids, such as plasmid DNA (pDNA), mRNA, siRNAs, and miRNAs, to cancer cells have attracted considerable interest. The cationic gene transporters commonly used are typically in the form of polyplexes, lipoplexes or mixtures of both, and their gene transfer efficiency in cancer cells depends on several factors, such as cell binding, intracellular trafficking, buffering capacity for endosomal escape, DNA unpacking, nuclear transportation, cell viability, and DNA protection against nucleases. Some of these factors influence other factors adversely, and therefore, it is of critical importance that these factors are balanced. Recently, with the advancements in contemporary tools and techniques, trigger-responsive nanoparticles with the potential to overcome their intrinsic drawbacks have been developed. This review summarizes the mechanisms and limitations of cationic gene transporters. In addition, it covers various triggers, such as light, enzymes, magnetic fields, and ultrasound (US), used to enhance the gene transfer efficiency of trigger-responsive gene transporters in cancer cells. Furthermore, the challenges associated with and future directions in developing trigger-responsive gene transporters for anticancer therapy are discussed briefly.
format Online
Article
Text
id pubmed-5485767
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54857672017-06-29 Trigger-Responsive Gene Transporters for Anticancer Therapy Rajendrakumar, Santhosh Kalash Uthaman, Saji Cho, Chong Su Park, In-Kyu Nanomaterials (Basel) Review In the current era of gene delivery, trigger-responsive nanoparticles for the delivery of exogenous nucleic acids, such as plasmid DNA (pDNA), mRNA, siRNAs, and miRNAs, to cancer cells have attracted considerable interest. The cationic gene transporters commonly used are typically in the form of polyplexes, lipoplexes or mixtures of both, and their gene transfer efficiency in cancer cells depends on several factors, such as cell binding, intracellular trafficking, buffering capacity for endosomal escape, DNA unpacking, nuclear transportation, cell viability, and DNA protection against nucleases. Some of these factors influence other factors adversely, and therefore, it is of critical importance that these factors are balanced. Recently, with the advancements in contemporary tools and techniques, trigger-responsive nanoparticles with the potential to overcome their intrinsic drawbacks have been developed. This review summarizes the mechanisms and limitations of cationic gene transporters. In addition, it covers various triggers, such as light, enzymes, magnetic fields, and ultrasound (US), used to enhance the gene transfer efficiency of trigger-responsive gene transporters in cancer cells. Furthermore, the challenges associated with and future directions in developing trigger-responsive gene transporters for anticancer therapy are discussed briefly. MDPI 2017-05-26 /pmc/articles/PMC5485767/ /pubmed/28587119 http://dx.doi.org/10.3390/nano7060120 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rajendrakumar, Santhosh Kalash
Uthaman, Saji
Cho, Chong Su
Park, In-Kyu
Trigger-Responsive Gene Transporters for Anticancer Therapy
title Trigger-Responsive Gene Transporters for Anticancer Therapy
title_full Trigger-Responsive Gene Transporters for Anticancer Therapy
title_fullStr Trigger-Responsive Gene Transporters for Anticancer Therapy
title_full_unstemmed Trigger-Responsive Gene Transporters for Anticancer Therapy
title_short Trigger-Responsive Gene Transporters for Anticancer Therapy
title_sort trigger-responsive gene transporters for anticancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485767/
https://www.ncbi.nlm.nih.gov/pubmed/28587119
http://dx.doi.org/10.3390/nano7060120
work_keys_str_mv AT rajendrakumarsanthoshkalash triggerresponsivegenetransportersforanticancertherapy
AT uthamansaji triggerresponsivegenetransportersforanticancertherapy
AT chochongsu triggerresponsivegenetransportersforanticancertherapy
AT parkinkyu triggerresponsivegenetransportersforanticancertherapy